GlassScriptPhysician profile
Lawrence H Lafond
NPI 1972598282
$1,330.58
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $273 · 2021: $433 · 2022: $369.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $211.86 | 2019-2021 | |
| Amarin Pharma, INC. | $198.24 | 2019-2021 | |
| Amgen INC. | $168.05 | 2019-2022 | |
| Pfizer INC. | $118.60 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.41 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $74.36 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $68.83 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.69 | 2022 | |
| Glaxosmithkline, LLC. | $50.78 | 2020-2021 | |
| Abbvie INC. | $50.04 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $48.58 | 2021 | |
| Orexo US, INC. | $25.73 | 2019-2021 | |
| Medicure Pharma INC. | $12.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.43 | 2022 | |
| Sanofi Pasteur INC. | $10.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Lafond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.